{"id":54797,"date":"2023-03-14T11:04:24","date_gmt":"2023-03-14T10:04:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-psychiatry-partnering-deal-trends-players-and-financials-directory-report-2016-2023-researchandmarkets-com\/"},"modified":"2023-03-14T11:04:24","modified_gmt":"2023-03-14T10:04:24","slug":"global-psychiatry-partnering-deal-trends-players-and-financials-directory-report-2016-2023-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-psychiatry-partnering-deal-trends-players-and-financials-directory-report-2016-2023-researchandmarkets-com\/","title":{"rendered":"Global Psychiatry Partnering Deal Trends, Players and Financials Directory\/Report 2016-2023 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Psychiatry Partnering 2016-2023: Deal trends, players and financials”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe report provides the full collection of psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.\n<\/p>\n

\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.\n<\/p>\n

\nThe report takes readers through the comprehensive psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering psychiatry deals.\n<\/p>\n

\nThe report presents financial deal terms values for psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.\n<\/p>\n

\nReport scope<\/strong>\n<\/p>\n

\nChapter 1 provides an introduction to the report.\n<\/p>\n

\nChapter 2 provides an overview of the trends in psychiatry dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.\n<\/p>\n

\nChapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.\n<\/p>\n

\nChapter 4 provides a review of the leading psychiatry deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\n<\/p>\n

\nChapter 5 provides comprehensive access to psychiatry deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.\n<\/p>\n

\nChapter 6 provides a comprehensive directory of all psychiatry partnering deals by specific psychiatry target announced since 2016. The chapter is organized by specific psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n

\nIn addition, a comprehensive appendix is provided with each report of all psychiatry partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n

\nThe report also includes numerous tables and figures that illustrate the trends and activities in psychiatry partnering and dealmaking since 2016.\n<\/p>\n

\nIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of psychiatry technologies and products.\n<\/p>\n

\nGlobal Psychiatry Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to psychiatry trends and structure of deals entered into by leading companies worldwide.\n<\/p>\n

\nGlobal Psychiatry Partnering 2016 to 2023 includes:<\/strong>\n<\/p>\n